As of Mar 24
| +0.82 / +2.43%|
The 9 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 52.00, with a high estimate of 68.00 and a low estimate of 26.00. The median estimate represents a +50.72% increase from the last price of 34.50.
The current consensus among 10 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.